İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2022

Intraductal tubulopapillary neoplasm ( ITPN ) of the pancreas: a distinct entity among pancreatic tumors

Dergi

Wiley

ISSN 0309-0167

ISSN kaydı başka bir dergiye işaret ediyor; ad YÖKSİS kaydından.

YÖKSİS OpenAlex Açık erişim · hybrid SJR Q1 JCR Q1 Atıf 29 Yüzdelik 89.3% FWCI 2.1
Yıl
2022
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • YÖKSİS dergi adı Wiley
  • Katalog eşleşmesi (ISSN) Histopathology
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

OpenAlex · İngilizce

AIMS: Intraductal tubulopapillary neoplasm (ITPN) of the pancreas is a recently recognized pancreatic tumor entity. Here we aimed to determine the most important features with a systematic review coupled with an integrated statistical approach. METHODS AND RESULTS: PubMed, SCOPUS, and Embase were searched for studies reporting data on pancreatic ITPN. The clinicopathological, immunohistochemical, and molecular data were summarized. Then a comprehensive survival analysis and a comparative analysis of the molecular alterations of ITPN with those of pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasm (IPMN) from reference cohorts (including the International Cancer Genome Consortium- ICGC dataset and The Cancer Genome Atlas, TCGA program) were conducted. The core findings of 128 patients were as follows: (i) Clinicopathological parameters: pancreatic head is the most common site; presence of an associated adenocarcinoma was reported in 60% of cases, but with rare nodal metastasis. (ii) Immunohistochemistry: MUC1 (>90%) and MUC6 (70%) were the most frequently expressed mucins. ITPN lacked the intestinal marker MUC2; unlike IPMN, it did not express MUC5AC. (iii) Molecular landscape: Compared with PDAC/IPMN, the classic pancreatic drivers KRAS, TP53, CDKN2A, SMAD4, GNAS, and RNF43 were less altered in ITPN (P < 0.001), whereas MCL amplifications, FGFR2 fusions, and PI3KCA mutations were commonly altered (P < 0.001). (iv) Survival analysis: ITPN with a "pure" branch duct involvement showed the lowest risk of recurrence. CONCLUSION: ITPN is a distinct pancreatic neoplasm with specific clinicopathological and molecular characteristics. Its recognition is fundamental for its clinical/prognostic implications and for the enrichment of potential targets for precision oncology.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

29 atıf

OpenAlex cited_by_count (önbellek / veritabanı)

Yazarlar

  1. G Paolino
  2. Irene Esposito
  3. SM Hong
  4. OLCA BAŞTÜRK
  5. P Mattiolo
  6. Kaneko T
  7. N Veronese
  8. Aldo Scarpa
  9. NAZMİ VOLKAN ADSAY KOÇ ÜNİVERSİTESİ
  10. C Luchini